Prosecution Insights
Prosecution Insights
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 3 (75%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROMERO, KRISTEN WANG | 1 | 71.4% | +29.6% |
| WILLIS, DOUGLAS M | 1 | 82.6% | +19.7% |
| SHOWALTER, ALEXANDER KEITH | 1 | 52.1% | +53.0% |
| LUNDE, GRACE HENRY | 1 | 63.6% | +37.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18024236 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | WILLIS, DOUGLAS M | 37d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17909162 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | ROMERO, KRISTEN WANG | 113d overdue |
| 18024159 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | SHOWALTER, ALEXANDER KEITH | 72d overdue |
| 18024236 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | WILLIS, DOUGLAS M | 37d overdue |
| 17610899 | ACTIVATABLE BISPECIFIC ANTIBODIES COMPRISING A LINKER BETWEEN THE TWO BINDING DOMAINS WHICH IS A HUMAN IMMUNOGLOBULIN HINGE REGION, OR A VARIANT THEREOF, AND USES THEREOF | LUNDE, GRACE HENRY | 19d |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1629 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17909162 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | ROMERO, KRISTEN WANG | 1624 | §112 | Non-Final OA | 113d overdue | Pending | Jul 06, 2023 |
| 18024236 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | WILLIS, DOUGLAS M | 1624 | §112 | Non-Final OA | 37d overdue | Pending | Mar 01, 2023 |
| 18024159 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | SHOWALTER, ALEXANDER KEITH | 1629 | Other | Non-Final OA | 72d overdue | Pending | Mar 01, 2023 |
| 17610899 | ACTIVATABLE BISPECIFIC ANTIBODIES COMPRISING A LINKER BETWEEN THE TWO BINDING DOMAINS WHICH IS A HUMAN IMMUNOGLOBULIN HINGE REGION, OR A VARIANT THEREOF, AND USES THEREOF | LUNDE, GRACE HENRY | 1641 | §112 | Final Rejection | 19d | Pending | Nov 12, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial